MBI: A mission inspired, market-driven biotech derisking hub
Rare among biotech hubs, MBI (Michigan Biotechnology Institute) is both a premier multidisciplinary center sought out by industry partners for unique derisking capabilities and a 501(c)(3) not-for-profit inspired by a mission to enhance quality of life by collaboratively accelerating the commercialization of sustainable biobased technologies.
Consistent with that mission, MBI shares select technologies – those that show the promise of game-changing sustainability – with the global community through low-cost, non-exclusive licensing.
Founded in 1981, MBI is a wholly owned subsidiary of the Michigan State University Foundation.
Trusted biotech accelerator
Technologies developed at MBI are recognized and trusted worldwide. To take just one example, consider that together with MSU and Cargill, MBI developed PLA, the polymer used worldwide to make renewable and biodegradable containers and cutlery.
MBI engages with universities, corporations and research institutions. Its long list of collaborators includes DuPont, Genomatica, Novozymes, NatureWorks and the Great Lakes Bioenergy Research Center.
Industry leader pioneering derisking
MBI is known in the industrial biotechnology field for pioneering derisking, a process that quickly and cost-effectively weeds out flawed technologies while accelerating viable ones. Seasoned MBI team members draw on expertise from science, engineering and business – and together, they roadmap, prioritize, and address technical and commercial risks to effectively and efficiently accelerate early-stage technologies to market-readiness.
MBI applies the derisking approach to the development of biofuels, chemicals, food and feed from renewable, rather than fossil, raw materials. Available technologies include fumaric acid, succinic acid and the AFEX platform technology.